References
- 1 Stahl SM. Atypical antipsychotics. Stahl's Essent. Psychopharmacol. Neurosci. Basis Pract. Appl.,. 4`thCambridge: Cambridge University Press, 2013:141–169.
- 2 Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-ofthe-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.10.2147/TCRM.S117321549979028721057
- 3 Kun IZ, Szántó Z, Kun I, et al. Konvencionális és atípusos antipszichotikumok okozta metabolikus szindróma. Orvostudományi Értesítő. 2017;90:7–18.
- 4 Citrome L. The ABC’s of dopamine receptor partial agonists - Aripiprazole, brexpiprazole and cariprazine: The 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69:1211–1220.10.1111/ijcp.1275226477545
- 5 Zimnisky R, Chang G, Gyertyán I, et al. Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013;226:91–100.10.1007/s00213-012-2896-5357227323079899
- 6 Corponi F, Fabbri C, Bitter I, et al. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29:971–985.10.1016/j.euroneuro.2019.06.00831255396
- 7 Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13:27–35.10.1038/sj.mp.400206617848919
- 8 Horn H, Böhme B, Dietrich L, et al. Endocannabinoids in body weight control. Pharmaceuticals. 2018;11:1–48.10.3390/ph11020055602716229849009
- 9 Bába L-I, Kolcsár M, Hack B, et al. Az endokannabinoid rendszer: receptoroktól a terápiáig (The endocannabinoid system: from the receptors to therapy). Orvostudományi Értesítő. 2019;92:1–14.
- 10 Pertwee RG, Howlett a C, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands : Beyond CB 1 and CB 2. Pharmacol Rev. 2010;62:588–631.10.1124/pr.110.003004299325621079038
- 11 Lu HC, MacKie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79:516–525.10.1016/j.biopsych.2015.07.028478913626698193
- 12 Faah - Fatty-acid amide hydrolase 1 - Rattus norvegicus (Rat) - Faah gene & protein. Available at https://www.uniprot.org/uniprot/P97612 Accessed August 21, 2020.
- 13 Mgll - Monoglyceride lipase - Rattus norvegicus (Rat) - Mgll gene & protein. Available at https://www.uniprot.org/uniprot/Q8R431 Accessed August 21, 2020.
- 14 Matias I, Belluomo I, Cota D. The Fat Side of the Endocannabinoid System: Role of Endocannabinoids in the Adipocyte. Cannabis Cannabinoid Res. 2016;1:176–185.10.1089/can.2016.0014
- 15 Gasperi V, Fezza F, Pasquariello N, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci. 2007;64:219–229.10.1007/s00018-006-6445-417187172
- 16 Perwitz N, Fasshauer M, Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res. 2006;38:356–358.10.1055/s-2006-92540116718635
- 17 Lazzari P, Serra V, Marcello S, et al. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats. Eur Neuropsychopharmacol. 2017;27:1–12.10.1016/j.euroneuro.2017.03.01028377074
- 18 Liebig M, Gossel M, Pratt J, et al. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity (Silver Spring). 2010;18:1952–1958.10.1038/oby.2010.1720168311
- 19 Minet-Ringuet J, Even PC, Valet P, et al. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry. 2007;12:562–571.10.1038/sj.mp.400194817211438
- 20 Bába L-I, Gáll Z, Kolcsár M, et al. Effect on Body Weight and Adipose Tissue by Cariprazine : A Head-to-Head Comparison Study to Olanzapine and Aripiprazole in Rats. Sci Pharm. 2020;88:1–14.10.3390/scipharm88040050
- 21 Weston-Green K, Huang XF, Deng C. Olanzapine treatment and metabolic dysfunction: A dose response study in female Sprague Dawley rats. Behav Brain Res. 2011;217:337–346.10.1016/j.bbr.2010.10.03921056063
- 22 De Santis M, Pan B, Lian J, et al. Different effects of Bifeprunox, Aripiprazole, and Haloperidol on body weight gain, food and water intake, and locomotor activity in rats. Pharmacol Biochem Behav. 2014;124:167–173.10.1016/j.pbb.2014.06.00424933333
- 23 Watson DJG, King M V., Gyertyán I, et al. The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Eur Neuropsychopharmacol. 2016;26:208–224.10.1016/j.euroneuro.2015.12.02026723167
- 24 Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659–661.10.1096/fj.07-9574LSF17942826
- 25 Eaton SL, Roche SL, Llavero Hurtado M, et al. Total Protein Analysis as a Reliable Loading Control for Quantitative Fluorescent Western Blotting. PLoS One. 2013;8:1–9.10.1371/journal.pone.0072457375829924023619
- 26 Moritz CP. Tubulin or Not Tubulin: Heading Toward Total Protein Staining as Loading Control in Western Blots. Proteomics. 2017;17:1–12.10.1002/pmic.20160018928941183
- 27 Welinder C, Ekblad L. Coomassie staining as loading control in Western blot analysis. J Proteome Res. 2011;10:1416–1419.10.1021/pr101147621186791
- 28 Skrede S, Martins L, Berge RK, et al. Olanzapine depot formulation in rat: A step forward in modelling antipsychotic-induced metabolic adverse effects. Int J Neuropsychopharmacol. 2014;17:91–104.10.1017/S146114571300086223919889
- 29 Weston-Green K, Huang XF, Deng C. Alterations to melanocortinergic, gabaergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PLoS One. 2012;7:1–12.10.1371/journal.pone.0033548330641122438946
- 30 Nisoli E. Endocannabinoids and obesity development - The adipose tissue. Drug Discov Today Dis Mech. 2010;7:e199–e204.10.1016/j.ddmec.2010.12.002
- 31 Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838–2843.10.2337/diabetes.54.10.2838222826816186383
- 32 Tam J, Godlewski G, Earley BJ, et al. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. Am J Physiol - Endocrinol Metab. 2014;306:E457-468.10.1152/ajpendo.00489.2013392309024381003
- 33 Hu Y, Young AJ, Ehli E a., et al. Metformin and berberine prevent olanzapine-induced weight gain in rats. PLoS One. 2014;9:1–9.
- 34 Skrede S, Fernø J, Vázquez MJ, et al. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol. 2012;15:163–179.10.1017/S146114571100127121854679
- 35 André A, Gonthier MP. The endocannabinoid system: Its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol. 2010;42:1788–1801.10.1016/j.biocel.2010.06.00220541029
- 36 Ruiz de Azua I, Lutz B. Multiple endocannabinoid-mediated mechanisms in the regulation of energy homeostasis in brain and peripheral tissues. Cell Mol Life Sci. 2019;76:1341–1363.10.1007/s00018-018-2994-630599065
- 37 Kale VP, Gibbs S, Taylor JA, et al. Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis. Regul Toxicol Pharmacol. 2019;109:1044983.
- 38 Barutta F, Bellini S, Mastrocola R, et al. Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. Br J Pharmacol. 2018;175:4371–4385.10.1111/bph.14495624013030184259
- 39 Tan S, Liu H, Ke B, et al. The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/β-arrestin1/Akt pathway. Br J Pharmacol. 2020;177:2830–2847.10.1111/bph.15010723606832017042